Intellia Therapeutics Announced Sunday At EAACI, Extended Phase 1 Data Reinforce Potential Of NTLA-2002 To Be A Functional Cure For People Living With Hereditary Angioedema
Portfolio Pulse from Charles Gross
Intellia Therapeutics announced updated interim results from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002, a CRISPR-based therapy for hereditary angioedema (HAE). The data showed durable elimination of HAE attacks after a single dose, with a favorable safety profile.
June 11, 2023 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intellia Therapeutics' NTLA-2002 shows promising Phase 1 results as a potential functional cure for hereditary angioedema, with a favorable safety profile.
The positive interim results from the Phase 1 study of NTLA-2002 indicate that the therapy has the potential to be a functional cure for hereditary angioedema. This could lead to increased interest in Intellia Therapeutics and its stock, as the company continues to develop and potentially commercialize this CRISPR-based therapy.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100